Kelly CRISPR & Gene Editing Technology ETF (XDNA)
Kelly CRISPR & Gene Editing Technology ETF operates in the Asset Management industry of the Financial Services sector, headquartered in Englewood, CO, CA. The stock last traded at $7.38, down 1.60% on the session, giving a market capitalisation of $2.6M. Its beta of 0.00 implies it has historically moved less than the broad market.
The fund employs a passive investment strategy, aiming to replicate the total return performance of its benchmark index. This index is rule-based, comprising equities or their corresponding depositary receipts from companies involved in the entire spectrum of DNA Modification Technology, including its invention, advancement, production, operation, provision, distribution, ownership, maintenance, licensing, leasing, or franchising. A minimum of 80% of the fund's net assets are dedicated to enterprises focused on DNA Modification Technology. This is a non-diversified fund.
Kelly CRISPR & Gene Editing Technology ETF is most often compared with the following Financial Services names: